Daniel J. George, MD
Findings from the phase III S-TRAC trial led to the FDA approval of sunitinib (Sutent) in November 2017 as an adjuvant therapy for patients with renal cell carcinoma (RCC) who are at high risk for recurrence. In a prospective study presented at the 2018 ASCO Annual Meeting, Daniel J. George, MD, reported on the disease-free survival (DFS) of patients at the highest risk of recurrence from S-TRAC.1
, George, professor of Medicine at Duke Cancer Center, discussed the analysis of RCC patients in the S-TRAC trial with the highest risk of recurrence, and potential prognostic factors of DFS that emerged from the study.
OncLive: Can you share some background on the rationale for the S-TRAC study?
S-TRAC was a phase III, prospective, multicenter study looking at the effectiveness of sunitinib versus placebo in patients at high risk for disease recurrence, particularly T3 or node-positive kidney cancer. In that prospective study, what we found [in the overall population] was that treatment with sunitinib for up to 1 year delayed DFS by about 24% with a hazard ratio of 0.76 and a P
value of .03. This was a 615-patient study.
... to read the full story